Construction method and application of oncolytic adenovirus carrying long-chain non-coding RNA H19 gene
By constructing an oncolytic adenovirus carrying the H19 gene, the problem of the unutilized H19 potential in the treatment of intrahepatic cholangiocarcinoma is solved, and the significant inhibition of intrahepatic cholangiocarcinoma cells is achieved, providing technology for drug research on intrahepatic cholangiocarcinoma. Base.
Patent Information
- Application Number
- CN202410903134.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-08
- Publication Date
- 2024-11-19
AI Technical Summary
In the prior art, the treatment methods for intrahepatic cholangiocarcinoma have not yet fully utilized the potential of long-chain non-coding RNA H19, and the application of oncolytic adenovirus in the study of intrahepatic cholangiocarcinoma is relatively limited, and there is a lack of effective inhibition of intrahepatic cholangiocarcinoma cells. method.
By constructing an oncolytic adenovirus carrying the H19 gene, the specific steps include constructing the plasmids PCD513-H19, pCA13-H19, pSD55-H19 and pAd5/3-H19, and obtaining the oncolytic adenovirus carrying the H19 gene through homologous recombination and packaging. SD55-H19 is used to inhibit intrahepatic cholangiocarcinoma cells.
This method significantly inhibits intrahepatic cholangiocarcinoma cells, provides new drug research ideas, provides a technical basis for the treatment of intrahepatic cholangiocarcinoma, and enhances the anti-tumor ability of the virus to intrahepatic cholangiocarcinoma through the overexpression of the H19 gene.
Smart Images

Figure CN118979063A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a construction method and application, and more specifically, to a construction method and application of an oncolytic adenovirus carrying a long non-coding RNA H19 gene, which belongs to the technical field of molecular biology. Background Art
[0002] Long noncoding RNA (lncRNA) H19 is expressed in the embryo, downregulated at birth, and then reappears in tumors. It actively participates in all stages of tumorigenesis and is expressed in almost all human cancers. H19 interacts with the tumor suppressor gene p53 to participate in cell proliferation and differentiation. In addition, it is also involved in epithelial to mesenchymal transition (EMT) and affects cell invasion ability. Many downstream targets and molecular pathways of H19 have been detected in cancer, including mirna, RUNX1, STAT3, β-catenin, Akt2 and FOXM1. Clinical studies have revealed the potential of lncRNA H19 as a biomarker and its correlation with poor prognosis. Increasing evidence shows that H19 plays a key role in tumor progression.
[0003] Oncolytic adenovirus is an icosahedral non-enveloped double-stranded DNA virus with a genome size of approximately 34-36kb. Its replication-related genes are mainly E1 to E4 genes. Certain gene deletions can improve the safety and oncolytic performance of adenovirus. For example, deleting E1A-CR2 can enhance the virus's ability to replicate in tumor cells. In addition, replacing the virus's E1A promoter with the liver cancer tissue-specific promoter alpha-fetoprotein AFP may also enhance the safety of the virus. SD55 is a new oncolytic adenovirus vector with E1B-55K and E3 deletions. It can express more exogenous inserted genes than Ad. It is reported that a dual-regulated oncolytic adenovirus Ad-wnt-E1A (△24bp)-TSLC1, also known as SD55-TSLC1, regulates the Wnt and Rb axes and carries the tumor suppressor gene TSLC1. SD55-TSLC1 can induce autophagic death of tumor cells. In vivo experiments have shown that the recombinant adenovirus can effectively induce apoptosis of liver cancer stem-like cells, inhibit tumor metastasis and growth, and prolong the survival of mice. This shows that oncolytic adenovirus is suitable as a viral vector for treating cancer and has great potential.
[0004] In the study of intrahepatic cholangiocarcinoma, H19 was confirmed to be a tumor suppressor gene. Oncolytic adenovirus also has strong anti-tumor ability against intrahepatic cholangiocarcinoma. There is almost no combined study of the two. Therefore, oncolytic adenovirus overexpressing H19 is of great significance in the study of intrahepatic cholangiocarcinoma. Summary of the invention
[0005] The purpose of the present invention is to provide a method for constructing and applying an oncolytic adenovirus carrying a long non-coding RNA H19 gene, which has a significant inhibitory effect on intrahepatic cholangiocarcinoma cells and provides a technical basis for drug research on intrahepatic cholangiocarcinoma.
[0006] In order to achieve the above object, the present invention is implemented by the following technical solutions:
[0007] In a first aspect, the present invention provides a method for constructing an oncolytic adenovirus carrying the H19 gene, comprising the following steps:
[0008] Step 1: construct plasmid pCD513-H19 carrying H19;
[0009] Step 2: construct plasmid pCA13-H19 carrying H19;
[0010] Step 3: construct plasmid pSD55-H19 carrying H19;
[0011] Step 4: Linearize and dephosphorylate the pSD55-H19, and then transform it into competent BJ5183-Adeasy5 / 35 / 3, and obtain the plasmid pAd5 / 3-H19 carrying the H19 gene after homologous recombination;
[0012] Step 5: The pAd5 / 3-H19 is linearized and dephosphorylated and then transfected into HEK293A cells. After packaging, the oncolytic adenovirus SD55-H19 carrying the H19 gene is obtained.
[0013] Preferably, step 1 includes the following sub-steps:
[0014] Step 1-1: Synthesize H19 gene;
[0015] Step 1-2: Connect the H19 to PCD513 to obtain the PCD513-H19.
[0016] In step 1-1, the base sequence of H19 is as follows:
[0017] agttagaaaaagcccgggctaggaccgaggagcagggtgagggagggggtgggatgggtggggggtaacgg
[0018] gggaaactggggaagtggggaaccgaggggcaaccaggggaagatggggtgctggaggagagcttgtggggagcca
[0019] aggagcaccttggacatctggagtctggcaggagtgatgacgggtggaggggctagctcgaggcagggctggtgggg
[0020] cctgaggccagtgaggagtgtggagtaggcgcccaggcatcgtgcagacagggcgacatcagctggggacgatgggc
[0021] ctgagctagggctggaaagaagggggagccaggcattcatcccggtcacttttggttacaggacgtggcagctggttgga
[0022] cgaggggagctggtgggcagggtttgatcccagggcctgggcaacggaggtgtagctggcagcagcgggcaggtga
[0023] ggaccccatctgccgggcaggtgagtcccttccctccccaggcctcgcttccccagccttctgaaagaaggaggtttagg
[0024] ggatcgagggctggcggggagaagcagacaccctcccagcagaggggcaggatgggggcaggagagttagcaaag
[0025] gtgacatcttctcggggggagccgagactgcgcaaggctggggggttatgggcccgttccaggcagaaagagcaaga
[0026] gggcagggagggagcacaggggtggccagcgtagggtccagcacgtggggtggtaccccaggcctgggtcagaca
[0027] gggacatggcaggggacacaggacagaggggtccccagctgccacctcacccaccgcaattcatttagtagcaggcac
[0028] aggggcagctccggcacggctttctcaggcctatgccggagcctcgagggctggagagcgggaagacaggcagtgct
[0029] cggggagttgcagcaggacgtcaccaggagggcgaagcggccacgggaggggggccccgggacattgcgcagcaa
[0030] ggaggctgcaggggctcggcctgcgggcgccggtcccacgaggcactgcggcccagggtctggtgcggagagggc
[0031] ccacagtggacttggtgacgctgtatgccctcaccgctcagcccctggggctggcttggcagacagtacagcatccagg
[0032] ggagtcaagggcatggggcgagaccagactaggcgaggcgggcggggcggagtgaatgagctctcaggagggagg
[0033] atggtgcaggcaggggtgaggagcgcagcgggcggcgagcgggaggcactggcctccagagcccgtggccaaggc
[0034] gggcctcgcgggcggcgacggagccgggatcggtgcctcagcgttcgggctggagacgaggccaggtctccagctg
[0035] gggtggacgtgcccaccagctgccgaaggccaagacgccaggtccggtggacgtgacaagcaggacatgacatggtc
[0036] cggtgtgacggcgaggacagaggaggcgcgtccggccttcctgaacaccttaggctggtggggctgcggcaagaagc
[0037] gggtctgtttctttacttcctccacggagtcggcacactatggctgccctctgggctcccagaacccacaacatgaaagaaa
[0038] tggtgctacccagctcaagcctgggcctttgaatccggCcacaaaaccctctagcttggaaatgaatatgctgcactttaca
[0039] accactgcactacctgactcaggaatcggctctggaaggtgaagctagaggaaccagacctcatcagcccaacatcaaa
[0040] gacaccatcggaacagcagcgcccgcagcacccaccccgcaccggcgactccatcttcatggccaccccctgcggcg
[0041] gacggttgaccaccagccaccacatcatcccagagctgagctcctccagcgggatgacgccgtccccaccacctccctct
[0042] tcttctttttcatccttctgtctctttgtttctgagctttcctgtctttccttttttctgagagattcaaagcctccacgactctgtttccc
[0043] ccgtcccttctgaatttaatttgcactaagtcatttgcactggttggagttgtggagacggccttgagtctcagtacgagtgtgc
[0044] gtgagtgtgagccaccttggcaagtgcctgtgcagggcccggccgccctccatctgggccgggtgactgggcgccggc
[0045] tgtgtgcccgaggcctcaccctgccctcgcctagtctggaagctccgaccgacatcacggagcagccttcaagcattccat
[0046] tacgccccatctcgctctgtgcccctccccaccagggcttcagcaggagccctggCctcatcatcaataaacactgttaca
[0047] gcaaaaaaaaaaaaaaaaa.
[0048] Preferably, step 2 comprises the following sub-steps:
[0049] Step 2-1: Double-digest PCD513-H19 and recover the H19 fragment.
[0050] Step 2-2: Double enzyme digestion of pCA13 vector and gel recovery.
[0051] Step 2-3: The recovered H19 is connected to the digested pCA13 by T4 ligase, and the plasmid carrying the H19 sequence (pCA13-H19) is obtained after transformation;
[0052] Preferably, the double enzyme digestion reaction system in steps 2-1 and 2-2 is: PCD513-H19 or PCA13 (1 μg), EcoRI (1 μL), BamHI (1 μL), 10× buffer (2 μL), and dd H2O to supplement the system volume to 20 μL.
[0053] The double enzyme digestion reaction conditions in steps 2-1 and 2-2 are: 37°C, overnight.
[0054] In step 2-3, the H19 digestion product and the digested pCA13 vector are first recovered by agarose gel electrophoresis, and then the two digestion products are connected by 2×Ligation high ver.2 ligase according to the preset molar mass ratio, and then the ligation product is transformed into competent DH5α, cultured, and extracted to obtain a plasmid carrying the H19 sequence (pCA13-H19).
[0055] Preferably, the concentration of agarose gel is 0.5-2%, for example: 0.5%, 0.7%, 1.0%, 1.3%, 1.5%, 1.7%, 2.0%.
[0056] Preferably, the time of agarose gel electrophoresis is 20 to 35 min, for example: 20 min, 25 min, 30 min, 35 min.
[0057] Preferably, the molar mass ratio of the two rubber tapping recovery products is pCA13:H19=1:3.
[0058] Preferably, the ligation temperature of pCA13 and H19 is 16°C.
[0059] Preferably, the connection time of pCA13 and H19 is 30-60 min.
[0060] Preferably, step 3 includes the following sub-steps:
[0061] Step 3-1: Enzyme digestion of the pCA13-H19, gel recovery of the 2937 bp fragment, enzyme digestion of the pSD55 plasmid, gel recovery after dephosphorylation and inactivation treatment
[0062] Step 3-2: The two plasmids treated in step 3-1 are connected by enzymes, and the pSD55 plasmid carrying the H19 sequence (pSD55-H19) is obtained through transformation.
[0063] Preferably, the enzyme in step 3-1 is BglⅡ.
[0064] Preferably, the pSD55 dephosphorylase is Fast AP.
[0065] Preferably, in step 3-2, the gel recovery products of pCA13-H19 and pSD55 are ligated with 2×Ligation high ver.2 and transformed into competent cells, and pSD55-H19 is obtained after culture and extraction.
[0066] Preferably, the concentration of agarose gel is 0.5-2%, for example: 0.5%, 0.7%, 1.0%, 1.3%, 1.5%, 1.7%, 2.0%.
[0067] Preferably, the time of agarose gel electrophoresis is 20 to 35 min, for example: 20 min, 25 min, 30 min, 35 min.
[0068] Preferably, the competent cell is one of DH5α, TG1, Mach1-T1, and XL10-Gold, and more preferably DH5α.
[0069] Preferably, step 4 includes the following sub-steps:
[0070] Step 4-1: The pSD55-H19 is digested with enzymes, and then linearized and dephosphorylated, and then recovered from the gel.
[0071] Step 4-2: The product obtained in step 4-1 was transfected into competent BJ5183-Adeasy5 / 3 for homologous recombination, and a plasmid carrying the H19 sequence (pAd-H19) was obtained after culture and extraction.
[0072] Preferably, the enzyme in step 4-1 mainly linearizes pSD55-H19, more preferably PmeⅠ, and the dephosphorylating enzyme is Fast AP.
[0073] Preferably, in step 4-2, the pSD55-H19 treated in step 4-1 is first subjected to agarose gel electrophoresis and then recovered by gel cutting, and the recovered product is transformed into competent BJ5183-Adeasy5 / 35 / 3, spread on a Kna-resistant LB plate, inverted culture and then single clones are picked, and the plasmid is extracted by shaking, and the plasmid is named pAd-H19.
[0074] Preferably, the temperature of the inverted culture is 37°C.
[0075] Preferably, the inverted culture time is 10 h or longer, more preferably 16 h or longer.
[0076] In another specific embodiment of the present invention, step 5 is the step of packaging pAd-H19.
[0077] Preferably, the pAd-H19 linearization reaction system includes: pAd-H19 (1 μg), PacI (1 μL), 10× buffer (2 μL), and dd H2O to supplement the system volume to 20 μL.
[0078] The linearization reaction conditions were: 37°C, enzyme digestion for 2 h.
[0079] Preferably, the pAd-H19 dephosphorylation reaction system includes: 20 μL of linearized product, 1 μL of Fast AP, 3 μL of Buffer, and 6 μL of ddH2O.
[0080] The dephosphorylation and inactivation reaction conditions were: 37°C for 30 min, then 75°C for 5 min. The dephosphorylating enzyme was Fast AP.
[0081] In a second aspect, the present invention provides the use of the oncolytic adenovirus constructed by the first aspect in the research and preparation of anti-intrahepatic cholangiocarcinoma products.
[0082] Preferably, the products include drugs, pharmaceutical raw materials, drug intermediates, targeted inhibitors, etc.
[0083] Preferably, the drug comprises an oncolytic adenovirus vaccine or an H19 gene.
[0084] Preferably, the drug further comprises pharmaceutically acceptable excipients.
[0085] Preferably, the auxiliary materials include an osmotic pressure regulator, a lyophilization protectant, a surfactant, a buffer, and an excipient.
[0086] Preferably, the osmotic pressure regulator includes sucrose, trehalose, mannitol, sorbitol. The lyophilization protective agent includes trehalose and sucrose. The buffer includes histidine, citric acid, succinic acid, acetate or phosphate;
[0087] The surfactant includes polysorbate 20, polysorbate 80, poloxamer 188 or polyethylene glycol 3350.
[0088] Beneficial effect: The method for constructing an oncolytic adenovirus carrying the H19 gene of the present invention provides a new idea and method for the study of intrahepatic cholangiocarcinoma. The H19 gene constructed using the technical scheme of the present application can have a significant inhibitory effect on intrahepatic cholangiocarcinoma cells, thereby providing a technical basis for the research on drugs for the treatment of intrahepatic cholangiocarcinoma. BRIEF DESCRIPTION OF THE DRAWINGS
[0089] Figure 1 Schematic diagram of the genome structure of oncolytic adenovirus carrying the H19 gene;
[0090] Figure 2 This is the result of double enzyme digestion of PCD513-H19 in Example 1;
[0091] Figure 3 This is a diagram showing the verification results of pCA13-H19 in Example 1;
[0092] Figure 4 This is a diagram showing the validation results of pSD55-H19 in Example 1;
[0093] Figure 5 This is a diagram showing the result of MluⅠ digestion of pAd-H19 in Example 1;
[0094] Figure 6 This is a diagram showing the identification results of the recombinant oncolytic adenovirus SD55-H19 and the wild-type virus in Example 2;
[0095] Figure 7 This is the second figure of the identification results of the recombinant oncolytic adenovirus SD55-H19 and the wild-type virus in Example 2;
[0096] Figure 8 This is a graph showing the expression of E1A protein and H19 gene in virus-infected intrahepatic cholangiocarcinoma cells detected by Western blot and RT-qPCR in Example 3;
[0097] Fig. 9 The second figure is the expression of E1A protein and H19 gene in virus-infected intrahepatic cholangiocarcinoma cells detected by Western blot and RT-qPCR in Example 3;
[0098] Fig.10 Figure 3 is the expression of E1A protein and H19 gene in virus-infected intrahepatic cholangiocarcinoma cells detected by Western blot and RT-qPCR in Example 3;
[0099] Fig.11This is the first result of MTT detection of cell survival rate of intrahepatic cholangiocarcinoma infected with SD55-H19 virus in Example 3;
[0100] Fig.12 The second figure is the result of MTT detection of cell survival rate of intrahepatic cholangiocarcinoma infected with SD55-H19 virus in Example 3;
[0101] Fig.13 The third figure is the result of MTT detection of cell survival rate of intrahepatic cholangiocarcinoma infected with SD55-H19 virus in Example 3;
[0102] Fig.14 The results of MTT detection of cell survival rate of intrahepatic cholangiocarcinoma infected with SD55-H19 virus in Example 3 are as follows: Figure 4 ;
[0103] Fig.15 This is one of the diagrams of the cytopathic effect of crystal violet in detecting viral infection of intrahepatic cholangiocarcinoma in Example 4;
[0104] Fig.16 This is the second diagram of the cell pathological effect of crystal violet after detecting virus infection of intrahepatic bile duct carcinoma in Example 4;
[0105] Fig.17 This is the third diagram of the cytopathic effect of crystal violet after detecting viral infection of intrahepatic bile duct carcinoma in Example 4;
[0106] Fig.18 This is a graph showing the results of qRT-PCR detection of the viral progeny replication ability of SD55-H19 in intrahepatic cholangiocarcinoma cells and normal intrahepatic bile duct cells in Example 4;
[0107] Fig.19 This is a graph showing the effect of injection of SD55-H19 and SD55-EGFP on the tumor volume in mice in Example 5;
[0108] Fig. 20 This is a HE staining result of tumors in mice infected with the virus in Example 5;
[0109] Fig.21 This is one of the results of Ki67 immunohistochemistry of tumors in mice infected with the virus in Example 5;
[0110] Fig. 22 The second figure is the Ki67 immunohistochemistry result of the tumor in the mouse after virus infection in Example 5;
[0111] Figure 6 Medium M: DL2000; 1: E3 positive; 2: E3 negative; 3: Viral genome PCR E3; 4: E1B 55K positive; 5: E1B 55K negative; 6: Viral genome PCR E1B55K; Figure 7 , 1: H19 positive; M: DL15000; 2: H19 negative; 3: Viral genome PCR H19;
[0112] Figure 8 The E1A protein expression in virus-infected intrahepatic cholangiocarcinoma cell lines HuCC-T1 and RBE; Figure 9-10 The expression of H19 gene in virus-infected intrahepatic cholangiocarcinoma cell lines HuCC-T1 and RBE;
[0113] The experimental data of each group in the above figure were statistically analyzed using GraphPad Prism 9 software to compare the data differences between different groups. The experimental data are expressed in the form of mean ± SD. If p < 0.05, a significant difference is marked, where p < 0.05 is marked with *, p < 0.01 is marked with **, p < 0.001 is marked with ***, and p < 0.0001 is marked with ****. All experiments were repeated three times. DETAILED DESCRIPTION
[0114] Below is a combination of the embodiments and the attached Figure 1-22 The technical scheme of the present invention will be further described, and the advantages and features of the present invention will become clearer with the description. However, it should be understood that the embodiments are only exemplary and do not limit the scope of the present invention. It should be noted that the experimental methods used in the following embodiments are conventional methods in the art unless otherwise specified.
[0115] Example 1 Construction of an oncolytic adenovirus carrying the H19 gene
[0116] 1.1 Construction of pCA13-H19
[0117] 1.1.1 Construction of plasmid pCD513-H19
[0118] H19 was synthesized according to the H19 sequence and then ligated to plasmid PCD513 to obtain PCD513-H19. PCD513-H19 was double-digested with EcoRI and BamHI to verify the results. Figure 2 .
[0119] Depend on Figure 2 It can be seen that EcoRI and BamHI double enzyme digestion cut at the corresponding restriction sites on PCD513-H19, and the corresponding two bands cut out are 8320bp (PCD513 vector) and 2362bp (carried H19 fragment), and the band sizes are correct.
[0120] 1.1.2 Obtaining pCA13-H19
[0121] First, PCD513-H19 and pCA13 vectors were double-digested with EcoRI and BamHI. Then, the PCD513-H19 and pCA13 vectors were electrophoresed at 120v on a 1% agarose gel for 30 min, and the H19 fragment and pCA13 vector were recovered using a gel tapping recovery kit (YOKANG Biological Product No.: YK00A2). The two gel tapping recovery products were connected by 2×Ligation high ver.2 (TOYOBO, LGK-201) at a molar mass ratio of pCA13:H19=1:3, and incubated at 16°C overnight. The ligation product was then transformed into competent DH5α, spread on a solid LB plate containing ampicillin, cultured at 37°C for 10-16h, and then a single clone plaque was picked and transferred to a liquid LB medium containing ampicillin. The culture was shaken at 220rpm for 10-16h, and then the recombinant vector was extracted using a plasmid extraction kit. BglⅡ single enzyme digestion verification was performed on pCA13-H19. The results are shown in Figure 3 .Depend on Figure 3 It can be seen that Bgl II cuts at the two Bgl II restriction sites on pCA13-H19, and the corresponding two bands cut out are 6357 bp (pCA13 vector) and 2937 bp (H19 expression cassette carried), and the band sizes are correct.
[0122] 1.3 Construction of pSD55-H19
[0123] First, use BglⅡ single enzyme to cut pCA13-H19 and pSD55 vectors respectively, and use Fast AP to dephosphorylate and inactivate pSD55. Then use 1% agarose gel 120v electrophoresis for 30 minutes for the two digested vectors, and use a gel tapping recovery kit (Youkang Biological Product No.: YK00A2) to recover the digested vectors. Use 2×Ligation high Ver.2 (TOYOBO, LGK-201) to connect the two gel tapping recovery products at 16°C overnight. Then transform the ligation product into competent DH5α, spread it on LB solid plate containing Kna, and culture it at 37°C for 10-12 hours. Pick out monoclonal plaques and transfer them to liquid LB medium containing Kna. Shake and culture at 220rpm for 10-16 hours, then use a plasmid extraction kit to extract the recombinant vector, and perform BglⅡ single enzyme cutting verification on pSD55-H19. The results are shown in Figure 4 .
[0124] The above-mentioned pSD55 was constructed by adding the Ad5 E1 region (deleting the E1B55 region) to the pShuttle plasmid.
[0125] Depend on Figure 4It can be seen that Bgl II cuts at the two Bgl II restriction sites on pSD55-H19, and the corresponding two bands cut out are 8637 bp (adenovirus plasmid vector) and 2937 bp (carried H19 fragment), and the band sizes are correct.
[0126] 1.4 Construction of pAd-H19
[0127] First, pSD55-H19 was cut with PmeⅠ enzyme to linearize pSD55-H19, and then dephosphorylated and inactivated. The digested vector was then electrophoresed on a 1% agarose gel at 120v for 30 minutes, and the digested vector was recovered using a gel tapping recovery kit (Youkang Biological Product Number: YK00A2). The recovered product was then transformed into the competent BJ5183-Adeasy5 / 3, spread on a Kna-resistant LB solid plate, inverted and cultured at 37°C for 10-16h, monoclonal plaques were picked, transferred to Kna-resistant liquid LB culture medium, shaken and cultured at 220rpm for 10-16h, and then the recombinant vector was extracted using a plasmid extraction kit. The pAd-H19 vector was verified using MluⅠ single enzyme digestion, and the results are shown in Figure 5 The verified plasmid was then transformed into DH5α competent cells, smeared on Kna-resistant LB plates, and plaques were picked to extract the plasmid. The plasmid was then verified by MluⅠ single enzyme digestion. The correct plasmid was pAd-H19 plasmid, and the pAd-H19 plasmid was sent to Youkang Biotech for sequencing.
[0128] Depend on Figure 5 It can be seen that after single enzyme digestion with MluⅠ, pAd-H19 produced 5 bands with sizes of approximately 1k bp, 1.8k bp, 4k bp, 5.8k bp, and 20k bp, respectively. The sizes of the 5 bands are correct.
[0129] 1.5 Build and package SD55-H19
[0130] 2 μg pAd-H19 plasmid extracted without endotoxin was linearized with PacⅠ single enzyme digestion, and then pAd-H19 was dephosphorylated and inactivated with Fast AP, and then diluted with serum-free medium and mixed. According to the mass ratio of plasmid: PEI = 1:3, PEI was diluted and mixed with serum-free medium, and then slowly dripped into the mixture of plasmid and serum-free medium, gently mixed, and allowed to stand at room temperature for 15 minutes. After standing, the mixture was added with 3×10 5 / well HEK293A 6-well plate, fresh 10% FBS cell culture medium was added to the 6-well plate. Placed in a 37°C 5% CO2 cell culture incubator, after culturing for 8 hours, the cell supernatant was discarded, replaced with fresh 5% FBS cell culture medium, and continued to culture for 7 days to observe the cell lesions. After the lesions, the supernatant and cells were collected to obtain the first generation virus, i.e., oncolytic adenovirus SD55-H19.
[0131] The above pAd-H19 linearization reaction system: pAd-H19 (2 μg), PacI (1 μL), 10× buffer (2 μL), and ddH2O to supplement the system volume to 20 μL.
[0132] The linearization reaction conditions were: 37°C, enzyme digestion for 2 h.
[0133] pAd-H19 dephosphorylation reaction system: linearized product 20μL, Fast AP 1μL, Buffer 3μL, ddH2O 6μL.
[0134] The dephosphorylation reaction conditions were: 37°C for 30 min, and then 75°C for 5 min to inactivate Fast AP.
[0135] Example 2 Identification of recombinant oncolytic adenovirus SD55-H19 and identification of wild-type virus
[0136] After the first generation virus was repeatedly frozen and thawed at -80℃ / 37℃ for three times, it was amplified by thin layer infection of HEK293A generation by generation, and a certain amount of virus liquid was extracted using a DNA virus genome extraction kit (Solebo, catalog number: D2400) to extract the recombinant oncolytic adenovirus genome. The virus genome was PCR-generated using H19, E1B55K, and E3 primers, and negative controls, positive controls, and experimental groups were set up for observation by agarose gel electrophoresis. The results are shown in Figure 6-7 .
[0137] Depend on Figure 6-7 It can be seen that the H19 sequence was successfully amplified; while the wild-type E1B55K and E3 sequences were not amplified.
[0138] Example 3 Verification of the infection results of recombinant oncolytic adenovirus SD55-H19 on intrahepatic cholangiocarcinoma cells
[0139] 3.1 Western blot detection of E1A protein expression in intrahepatic cholangiocarcinoma cells after virus infection
[0140] HuCC-T1 and RBE cell lines were plated in six-well plates (50w / well). After the cells adhered to the wall, oncolytic adenoviruses SD55-H19 and SD55-EGFP were added to the wells at 1MOI. The virus-free group was used as a control. After 48 hours, all cells in the wells were collected, proteins were extracted, and western blot was performed to identify the expression of E1A protein. The results are shown in Figure 8 .Depend on Figure 8 It can be seen that both SD55-EGFP and SD55-H19 can successfully infect intrahepatic cholangiocarcinoma cells HuCC-T1 and RBE.
[0141] 3.2 RT-qPCR detection of H19 expression in intrahepatic cholangiocarcinoma cells after virus infection
[0142] HuCC-T1 and RBE cell lines were plated in six-well plates (50w / well). After the cells adhered to the wall, oncolytic adenoviruses SD55-H19 and SD55-EGFP were added to the wells at 1MOI. The virus-free group was used as a control. After 48 hours, all cells in the wells were collected, RNA was extracted, reverse transcribed into cDNA, and RT-qPCR was performed to identify the expression of H19. The results are shown in Fig. 9 .Depend on Fig. 9 It can be seen that both SD55-EGFP and SD55-H19 can successfully overexpress H19 after infecting intrahepatic cholangiocarcinoma cells.
[0143] Example 4 Effect of recombinant oncolytic adenovirus SD55-H19 on the growth of intrahepatic cholangiocarcinoma cells
[0144] 4.1 MTT assay to detect cell survival rate of intrahepatic cholangiocarcinoma cells after virus infection
[0145] 4.1.1 MTT assay
[0146] At the sampling time point, 20 μL MTT (5 mg / mL) was added to each well of the cell culture plate. After incubation in the cell culture incubator for 4 hours, the cell supernatant was aspirated, 150 μL DMSO was added to each well, and after mixing on a shaker for 10 minutes, the OD value was measured at 490 nm on a microplate reader, and the cell survival rate was calculated based on the OD value. The specific formula is as follows:
[0147] Cell viability (%) = (OD of virus-infected wells - OD of blank wells) / (OD of control wells - OD of blank wells) × 100%.
[0148] 4.1.2 Cell survival rate detection of intrahepatic cholangiocarcinoma cell lines
[0149] The low-expression H19 intrahepatic cholangiocarcinoma lines HuCC-T1 and RBE were used as experimental cell lines, and each cell line was plated in a 96-well plate (3000 / well, 100 μL / well). After the cells adhered to the wall, oncolytic adenovirus SD55-EGFP (without the target gene) and SD55-H19 with MOIs of 0, 1, 5, 10, 20, and 40 were added to the 96-well plate. Five replicate wells were set for each MOI group. Samples were taken at 24 hours to determine the cell survival rate of each cell line. The results are shown in Figure 11-12 After the cells adhered to the wall, the oncolytic adenovirus SD55-EGFP (without the target gene) and SD55-H19 with an MOI of 1 were added to a 96-well plate. Five replicate wells were set for each MOI group. Samples were taken at 24h, 48h, 72h, and 96h to determine the cell survival rate of each cell line. The results are shown in Figure 13-14 .
[0150] Depend on Figure 11-12 It can be seen that SD55-EGFP and SD55-H19 have obvious inhibitory effects on intrahepatic cholangiocarcinoma cells HuCC-T1 and RBE, and the higher the virus infection multiplicity, the stronger the killing effect on intrahepatic cholangiocarcinoma cell lines. Compared with SD55-EGFP, SD55-H19 has a stronger inhibitory effect on intrahepatic cholangiocarcinoma. Figure 13-14 It can be seen that the killing effect of SD55-EGFP and SD55-H19 on intrahepatic cholangiocarcinoma cells HuCC-T1 and RBE is obviously time-dependent, and the killing effect is stronger as time increases. This shows that the treatment effect of the virus is dose-dependent and time-dependent, and in the H19 low-expressing cell line, the SD55-H19 virus has a better killing effect on intrahepatic cholangiocarcinoma.
[0151] 4.2 Crystal violet method to quantify the pathological effects of intrahepatic cholangiocarcinoma cells after viral infection
[0152] 4.2.1 Crystal violet experimental method
[0153] After 48 hours of virus addition, the supernatant was discarded, the cells were gently washed twice with PBS, 200 ul of crystal violet solution (0.2% crystal violet) was added for staining for 20 min, and then the excess crystal violet was removed by rinsing. Each well was photographed under a microscope, and the images were processed with ImageJ for cell counting. Cell survival rate (%) = number of cells in virus-infected wells / number of cells in control group × 100%.
[0154] 4.2.2 Pathological effects of intrahepatic cholangiocarcinoma cells after viral infection
[0155] The low-expression H19 intrahepatic cholangiocarcinoma lines HuCC-T1 and RBE were used as experimental cell lines, and each cell line was plated in a 24-well plate (60000 / well, 500μL / well). After the cells adhered to the wall, the oncolytic adenovirus SD55-EGFP (without the target gene) and SD55-H19 with MOI of 0, 10, 20, 30, and 40 were added to the 6-well plate. Three replicate wells were set for each MOI group. Crystal violet staining was performed at 48 hours, and the cell lesions were observed under a microscope, photographed, and quantified by imagej. The results are shown in Figure 15-17 .
[0156] Depend on Figure 15-17 It can be seen that both SD55-EGFP and SD55-H19 significantly caused cytopathic effects on intrahepatic cholangiocarcinoma cells HuCC-T1 and RBE, and the higher the multiplicity of infection, the more severe the cytopathic effects. At the same multiplicity of infection, SD55-H19 was more likely to cause cytopathic effects than SD55-EGFP.
[0157] Example 4 RT-qPCR detection of the difference in the progeny replication ability of SD55-H19 in intrahepatic cholangiocarcinoma cells and normal intrahepatic bile duct epithelial cells
[0158] 4.1 Preparation of standard solution (using plasmid pAd-H19 as standard)
[0159] The concentration of the standard DNA was determined by Nano2000, and the copy number of the standard DNA was calculated according to the formula, and then diluted to 1x10 with ddH2O. 9 , 1x10 8 , 1x10 7 , 1x10 6 , 1x10 5 , 1x10 4 , 1x10 3 copies / μL (Formula: copies / μL = 6.02 x 10 23 x DNA concentration (ng / μL) x 10 -9 / relative molecular mass MW); dsDNA MW = number of base pairs x 660.
[0160] 4.2 Detection of the replication capacity of SD55-H19 progeny
[0161] Intrahepatic ductal carcinoma cells and normal intrahepatic bile duct epithelial cells were plated in six-well plates at 500,000 / well. After adherence, the virus was added at 1 MOI. The supernatant culture solution and adherent cells were collected at 24, 48, 72, and 96 hours. The liquid nitrogen was repeatedly frozen and thawed 3 times, and centrifuged at 3000 rpm for 5 minutes. 500 μl of supernatant was taken to extract the viral genome using the viral genome extraction kit (Solebo, catalog number: D2400). Hexon was amplified by RT-qPCR using Hexon qPCR primers to obtain the CT value, and the number of viral particles was calculated based on the standard curve. The results are shown in Fig.18 .Depend on Fig.18 It can be seen that the production of SD55-H19 viral progeny in intrahepatic cholangiocarcinoma cells HuCC-T1 and RBE increases with time, and in the same time period, the number of progeny viral particles in HuCC-T1 and RBE are significantly higher than that in normal cells Hebipic.
[0162] RT-qPCR reaction system: 2×HieffqPCR SYBR Green Master Mix (10 μL), upstream primer E1A-qPCR F (SEQ ID NO: 8) 10 μM 0.4 μL, downstream primer E1A-qPCR R (SEQ ID NO: 9) 10 μM 0.4 μL, template DNA 1 μL, and sterile ultrapure water to make up the volume to 20 μL.
[0163] PCR amplification program: 95°C for 5 min pre-denaturation, 95°C for 10 s denaturation, 60°C for 30 s annealing, 35 cycles.
[0164] Among them, Ad Hexon Q-PCR F: 5'-ATGGTCGCTATGTGCCCTTC-3'
[0165] Ad Hexon Q-PCR R:5'-CTGGCTCCGTCAACCCTTAG-3'
[0166] Example 5 Animal Experiment
[0167] 5.1 Inhibitory effect of recombinant oncolytic adenovirus SD55-H19 on intrahepatic cholangiocarcinoma cells in vivo
[0168] 4-5 week old female M-NSG mice were used and housed under SPF conditions. Each mouse was injected subcutaneously with 1×10 7 HuCC-T1 cells. Tumors formed in more than one week, with a size of 100 mm 3The mice were randomly divided into 3 groups: PBS control group, SD55-EGFP treatment group and SD55-H19 group, with 8 mice in each group. PBS, SD55-EGFP and SD55-H19 virus (5×10 8 PFU / mice / day), and the tumor volume was measured every 4 days for more than 20 days. When the tumor size reached 2000mm 3 Euthanize the mice when ethically necessary and calculate the tumor volume according to the following formula.
[0169] Tumor volume (mm 3 ) = length (mm) × width (mm) 2 ×0.5.
[0170] Results Fig.19 ,Depend on Fig.19 It can be seen that as time goes by, the injection of SD55-H19 significantly inhibits tumor growth compared with the PBS group; it also has a better effect on inhibiting tumor growth compared with the injection of SD55-EGFP group; this indicates that the injection of SD55-H19 has the best effect on inhibiting tumor growth and can significantly inhibit tumor growth, which has a certain reference value for the treatment of intrahepatic cholangiocarcinoma.
[0171] 5.2HE staining and Ki67 immunohistochemistry to verify the killing effect of SD55-H19 in vivo
[0172] After the mice were euthanized, the tumor tissues of the mice were separated and a portion was fixed with 4% paraformaldehyde tissue fixative for HE staining. Fig. 20 ; A portion was used for Ki67 immunohistochemistry detection, the results are shown in Figure 21-22 .
[0173] Depend on Fig. 20 It can be seen that the range of tumor cell death in the SD55-H19 treatment group is more extensive than that in the SD55-EGFP or PBS control group; Figure 21-22 It can be seen that the expression level of proliferation-related Ki67 antigen in the SD55-H19 group was significantly reduced compared with that in the SD55-EGFP or PBS control group, indicating that the virus has a better ability to inhibit tumor growth.
[0174] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.
Claims
1. A method for constructing an oncolytic adenovirus carrying a long noncoding RNA H19 gene, characterized in that The method comprises the following steps: Step 1: construct plasmid pCD513-H19 carrying H19; Step 2: Plasmid pCA13-H19 carrying the H19; Step 3: construct plasmid pSD55-H19 carrying the H19 sequence; Step 4: Linearize and dephosphorylate the pSD55-H19, and then transform it into competent BJ5183-Adeasy5 / 3 to obtain the plasmid pAd-H19 carrying the H19 sequence after homologous recombination; Step 5: The pAd-H19 is linearized and dephosphorylated and then transfected into HEK293A cells. After packaging, the oncolytic adenovirus SD55-H19 carrying the long non-coding RNA H19 gene is obtained.
2. The method for constructing an oncolytic adenovirus carrying a long noncoding RNA H19 gene according to claim 1, characterized in that: The step 1 includes the following sub-steps: Step 1-1: Synthesize long noncoding RNA H19; Step 1-2: Connect the H19 to PCD513 to obtain the PCD513-H19.
3. The method for constructing an oncolytic adenovirus carrying a long noncoding RNA H19 gene according to claim 1, characterized in that: The step 2 includes the following sub-steps: Step 2-1: double-digest the PCD513-H19 and pCA13 vectors; Step 2-2: Recover the H19 fragment and pCA13 vector after double enzyme digestion; Step 2-3: The H19 obtained by the enzyme digestion and the pCA13 obtained by the enzyme digestion are connected by ligase and transformed into competent DH5α to obtain the plasmid pCA13-H19 carrying H19.
4. The method for constructing an oncolytic adenovirus carrying the long noncoding RNA H19 gene according to claim 3, characterized in that: The step 3 includes the following sub-steps: Step 3-1: digest the pCA13-H19 and plasmid pSD55, and then dephosphorylate and inactivate pSD55; Step 3-2: The two plasmids treated in step 3-1 are connected with enzymes, and then transformed into competent cells. After culture, extraction and identification, the pSD55-H19 is obtained.
5. The method for constructing an oncolytic adenovirus carrying the long noncoding RNA H19 gene according to claim 4, characterized in that: The enzymes in step 2-1 are EcoRI and BamH I, the enzyme in step 3-1 is BglⅡ, and the competent cells for transformation in step 3-2 are selected from DH5α.
6. The method for constructing an oncolytic adenovirus carrying the long noncoding RNA H19 gene according to claim 1, characterized in that: The step 4 includes the following sub-steps: Step 4-1: digest the pSD55-H19, and then perform linearization and dephosphorylation treatment; Step 4-2: The product obtained in step 4-1 was transformed into competent BJ5183-Adeasy5 / 3, cultured and extracted, and the pAd-H19 was obtained after identification.
7. Use of the construction method according to any one of claims 1 to 6 in the preparation of an anti-intrahepatic cholangiocarcinoma product, characterized in that: The products include drugs, pharmaceutical raw materials or targeted inhibitors.
8. The use of claim 7 in preparing an anti-intrahepatic cholangiocarcinoma product, characterized in that: The drugs include oncolytic adenovirus vaccines or long non-coding RNA H19.
9. The use of claim 8 in preparing an anti-intrahepatic cholangiocarcinoma product, characterized in that: The drug also includes pharmaceutically acceptable excipients.
10. The use of claim 9 in preparing an anti-intrahepatic cholangiocarcinoma product, characterized in that: The auxiliary materials include osmotic pressure regulator, lyophilization protectant, surfactant, buffer and excipient.
